Literature DB >> 9721430

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.

A J Nicholls1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9721430     DOI： 10.1016/s0009-9120(98)00056-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN： 0009-9120            Impact factor:   3.281


× No keyword cloud information.
  10 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?

Authors:  Michel Mourad; Pierre Wallemacq; Josiane König; Evelyne Henry de Frahan; Djamila Chaib Eddour; Martine De Meyer; Jacques Malaise; Jean Paul Squifflet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.

Authors:  Caroline Streicher; Sarah Djabarouti; Fabien Xuereb; Estibaliz Lazaro; Rachel Legeron; Stéphane Bouchet; Carine Greib; Dominique Breilh; Jean-Luc Pellegrin; Jean-François Viallard
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 5.  The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.

Authors:  Catherine M T Sherwin; Tsuyoshi Fukuda; Hermine I Brunner; Jens Goebel; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2011-01       Impact factor: 6.447

6.  A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.

Authors:  Aurélie Prémaud; Jean Debord; Annick Rousseau; Yannick Le Meur; Olivier Toupance; Yvon Lebranchu; Guillaume Hoizey; Chantal Le Guellec; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.

Authors:  Chantal Le Guellec; Hélène Bourgoin; Matthias Büchler; Yann Le Meur; Yvon Lebranchu; Pierre Marquet; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.

Authors:  B Shum; S B Duffull; P J Taylor; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

9.  Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients.

Authors:  Sabine Irtan; Said Azougagh; Caroline Monchaud; Michel Popon; Véronique Baudouin; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

10.  Usefulness of limited sampling strategy for mycophenolic acid area under the curve considering postoperative days in living-donor renal transplant recipients with concomitant prolonged-release tacrolimus.

Authors:  Tomoyuki Enokiya; Kouhei Nishikawa; Yuichi Muraki; Takuya Iwamoto; Hideki Kanda; Yoshiki Sugimura; Masahiro Okuda
Journal:  J Pharm Health Care Sci       Date:  2017-06-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.